Prothena (FRA:0PT) Minority Interest: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0PT Prothena Corp PLC FRA:0PT
75 GF Score
Price €7.83
GF Value €11.00
! 2 Warning Signs
View Full Analysis

What is Prothena Minority Interest?

Prothena FRA:0PT +1.19% 75 Minority Interest is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:0PT with a GF Score™ of 75/100 and a GF Value™ of €11.00. The stock has 2 warning signs investors should review.

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Prothena's minority interest for the quarter that ended in Jun. 2026 was €0.00 Mil.

Prothena Minority Interest Historical Data

* Premium members only.

The historical data trend for Prothena's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prothena Minority Interest Chart

Prothena Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Minority Interest
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Prothena Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:0PT
75GF Score
Prothena Corp PLC FRA:0PT
Minority Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prothena Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Frequently Asked Questions Learn more about Minority Interest →
What does a Minority Interest of €0.00 Mil mean?
Prothena (FRA:0PT) has a Minority Interest of €0.00 Mil as of Jun. 2026. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Prothena.
Is Prothena's Minority Interest too high?
Prothena's current Minority Interest is €0.00 Mil. Overall, Prothena has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Prothena's Minority Interest compare to KYTX and QTTB?
Prothena's Minority Interest of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Minority Interest for a Biotechnology company?
A good Minority Interest depends on the Biotechnology industry context. However, Minority Interest should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Minority Interest mean?
A high Minority Interest can signal that a stock is expensive relative to its fundamentals. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Prothena. Prothena's current Minority Interest is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prothena stock overvalued right now?
Prothena (FRA:0PT) has a current Minority Interest of €0.00 Mil. The stock's GF Value™ is €11.00, compared to a current price of €7.83 — trading 28.8% below its estimated fair value. The current Minority Interest is €0.00 Mil. Prothena's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Minority Interest calculated?
Minority Interest is calculated from a company's financial statements. For Prothena (FRA:0PT), the current Minority Interest is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prothena (FRA:0PT) Overvalued in 2026?

Based on GuruFocus' analysis, Prothena stock appears to be undervalued. The current stock price of €7.83 is trading 28.8% below its estimated GF Value™ of €11.00.

Key valuation signals for FRA:0PT:

  • Minority Interest: €0.00 Mil
  • GF Value™: €11.00 vs. price of €7.83 (28.8% below fair value)
  • GF Score™: 75/100 with 2 warning signs

No single metric tells the full story. See the FRA:0PT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prothena Business Description

Other Exchanges PRTA:USA0Y3M:UK
Address 77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, Dublin, IRL, D02 VK60
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
75GF Score

Get the complete analysis for FRA:0PT

Minority Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.83
Price
€11.00
GF Value